We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).
We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.
Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.
Redx Pharma
Key Phase II data for lead assets expected during H223HUTCHMED
Takeda licenses fruquintinib in $1.13bn ex-China dealAvacta
AVA6000 shows signs of successful tumour targettingArecor Therapeutics
Hikma licence milestone achievedANGLE
FY22: a year of two very distinct halvesAllergy Therapeutics
Annual report and accounts delayed, shares suspendedArecor Therapeutics
Getting the chemistry rightRedx Pharma
Laying the foundations for further delivery in 2023HUTCHMED
First steps towards fruquintinib availability in the USAvacta
Diagnostics business back into the spotlight